Genprex, Inc. (GNPX)
| Market Cap | 75.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.83M |
| Shares Out | 47.90M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,473 |
| Open | 1.56 |
| Previous Close | 1.56 |
| Day's Range | 1.53 - 1.60 |
| 52-Week Range | 1.17 - 4.07 |
| Beta | -1.04 |
| Analysts | Buy |
| Price Target | 6.63 (+322.8%) |
| Earnings Date | May 16, 2022 |
About GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for GNPX stock is "Buy." The 12-month stock price forecast is 6.63, which is an increase of 322.83% from the latest price.
News
Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference
Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors AUSTIN, Texas , May 9, 2022 /PRNewswire/ -- Genprex...
Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or...
Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022
Presentations to highlight the Company's gene therapies for cancer and diabetes AUSTIN, Texas , April 18, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-sta...
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces it has opened its Acclaim-2 clinical trial for patient enrollment.
Genprex to Participate in Upcoming Investor Conference in March
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in March conferences.
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combina...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces the dosing of its first patient in its Acclaim-1 clinical trial in non-small cell lung cancer
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in February conferences.
4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News
4 names for your penny stocks list this week. The post 4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Preclinical Data Show Potential for Use of Genprex's ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Preclinical data finds that Genprex's ONCOPREX Nanoparticle Delivery System may be a potential platform for colon cancer
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell ...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial.
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company's Gene Therapies in Cancer...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces its conference participation for January 2022.
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag
The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Genprex expands its clinical development pipeline to include Small Cell Lung Cancer.
Genprex up by 130% after receiving FDA fast track designation
Genprex Inc (NASDAQ: GNPX) is a clinical-stage gene therapy organization that concentrates on the development of life-changing gene therapies to treat people with diabetes and cancer. The company announ...
Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatment
Shares of Genprex Inc. GNPX, +121.37% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designatio...
GNPX Stock: 5 Things to Know as Genprex Rockets Higher
Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. The post GNPX Stock: 5 Things to Know as Genprex Rockets Higher...
8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE
We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. The post 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GN...
Why Genprex Shares Are Soaring Today
Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA Immunogene Therapy in combination w...
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting
The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc's (NY...
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for th...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex Received FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Keytruda for Non-Small Cell Lung Cancer
Genprex to Present in November CEO Roadshow Webinar
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on November 17 at 11 a.m. ET with CEO Roadshow.
5 Top Penny Stocks To Buy For Under $5 On Webull Today
Are these penny stocks on your Webull watch list? The post 5 Top Penny Stocks To Buy For Under $5 On Webull Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...
Genprex to Participate in September Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...